Gene content  |
| PTPN11 ( by HUGO) |
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 |
| Oncogene |
| Protein Tyrosine Phosphatase Non-Receptor Type 11 NS1 PTP2C Protein-Tyrosine Phosphatase 1D Protein-Tyrosine Phosphatase 2C PTP-1D PTP-2C SH-PTP2 SH-PTP3 EC 3.1.3.48 SHP2 Noonan Syndrome 1 BPTP3 CFC Tyrosine-Protein Phosphatase Non-Receptor Type 11 SHP-2 SHPTP2 Shp2 |
| NCBI: 12q24 Ensembl: 12q24.13 |
|
Subunit: Interacts with phosphorylated LIME1 and BCAR3. Interacts with SHB and INPP5D/SHIP1 (By similarity). Interacts with MILR1 (tyrosine-phosphorylated). Interacts with FLT1 (tyrosine-phosphorylated), FLT3 (tyrosine-phosphorylated), FLT4 (tyrosine-phosphorylated), KIT and GRB2. Interacts with PDGFRA (tyrosine phosphorylated). Interacts (via SH2 domain) with TEK/TIE2 (tyrosine phosphorylated) (By similarity). Interacts with PTPNS1 and CD84. Interacts with phosphorylated SIT1 and MPZL1. Interacts with FCRL3, FCRL4, FCRL6 and ANKHD1. Interacts with KIR2DL1; the interaction is enhanced by ARRB2. Interacts with GAB2. Interacts with TERT; the interaction retains TERT in the nucleus. Interacts with PECAM1 and FER. Interacts with EPHA2 (activated); participates in PTK2/FAK1 dephosphorylation in EPHA2 downstream signaling. Interacts with ROS1; mediates PTPN11 phosphorylation. Interacts with PDGFRB (tyrosine phosphorylated); this interaction increases the PTPN11 phosphatase activity. Interacts with GAREM isoform 1 (tyrosine phosphorylated); the interaction increases MAPK/ERK activity and does not affect the GRB2/SOS complex formation Selected PDB 3D structures from [IMAGE] and Proteopedia [IMAGE] for PTPN11 (see all 13): 2SHP (3D) [IMAGE] 3B7O (3D) [IMAGE] 3MOW (3D) [IMAGE] 3O5X (3D) [IMAGE] 3TKZ (3D) [IMAGE] 3TL0 (3D) [IMAGE]
Tissue specificity: Widely expressed, with highest levels in heart, brain, and skeletal muscle [IMAGE] Pathway & Disease-focused RT2 Profiler PCR Arrays including PTPN11: Multiple Sclerosis in human mouse rat PI3K-AKT Signaling Pathway in human mouse rat Protein Phosphatases
Function: Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Dephosphorylates ROCK2 at Tyr-722 resulting in stimulatation of its RhoA binding activity Acts downstream of various receptor and cytoplasmic protein tyrosine kinases to participate in the signal transduction from the cell surface to the nucleus. Dephosphorylates ROCK2 at Tyr-722 resulting in stimulatation of its RhoA binding activity
Catalytic activity: Protein tyrosine phosphate + H(2)O = protein tyrosine + phosphate
Similarity: Belongs to the protein-tyrosine phosphatase family. Non-receptor class 2 subfamily Contains 2 SH2 domains Contains 1 tyrosine-protein phosphatase domain [IMAGE]
|
| Disorder & Mutation |
| Source |
Disease |
| SWISS-PROT | LEOPARD syndrome 1 (LEOPARD1) [MIM:151100]: A disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness. Note=The disease is caused by mutations affecting the gene represented in this entry |
| SWISS-PROT | Noonan syndrome 1 (NS1) [MIM:163950]: A form of Noonan syndrome, a disease characterized by short stature, facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears, and a high incidence of congenital heart defects and hypertrophic cardiomyopathy. Other features can include a short neck with webbing or redundancy of skin, deafness, motor delay, variable intellectual deficits, multiple skeletal defects, cryptorchidism, and bleeding diathesis. Individuals with Noonan syndrome are at risk of juvenile myelomonocytic leukemia, a myeloproliferative disorder characterized by excessive production of myelomonocytic cells. Some patients with NS1 develop multiple giant cell lesions of the jaw or other bony or soft tissues, which are classified as pigmented villonodular synovitis (PVNS) when occurring in the jaw or joints. Note=The disease is caused by mutations affecting the gene represented in this entry. Mutations in PTPN11 account for more than 50% of the cases |
| SWISS-PROT | Leukemia, juvenile myelomonocytic (JMML) [MIM:607785]: An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages. Note=The disease is caused by mutations affecting the gene represented in this entry |
